AU2003301224C1 - Pyrazole derivatives modulators of Hepatocyte Growth Factor (Scatter Factor) activity - Google Patents

Pyrazole derivatives modulators of Hepatocyte Growth Factor (Scatter Factor) activity Download PDF

Info

Publication number
AU2003301224C1
AU2003301224C1 AU2003301224A AU2003301224A AU2003301224C1 AU 2003301224 C1 AU2003301224 C1 AU 2003301224C1 AU 2003301224 A AU2003301224 A AU 2003301224A AU 2003301224 A AU2003301224 A AU 2003301224A AU 2003301224 C1 AU2003301224 C1 AU 2003301224C1
Authority
AU
Australia
Prior art keywords
optionally substituted
alkoxy
independently selected
hydroxy
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003301224A
Other languages
English (en)
Other versions
AU2003301224A1 (en
AU2003301224B2 (en
Inventor
David Eiznhamer
David E. Zembower
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of AU2003301224A1 publication Critical patent/AU2003301224A1/en
Publication of AU2003301224B2 publication Critical patent/AU2003301224B2/en
Application granted granted Critical
Publication of AU2003301224C1 publication Critical patent/AU2003301224C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003301224A 2002-12-21 2003-12-19 Pyrazole derivatives modulators of Hepatocyte Growth Factor (Scatter Factor) activity Ceased AU2003301224C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43553302P 2002-12-21 2002-12-21
US60/435,533 2002-12-21
US10/740,708 2003-12-18
US10/740,708 US7192976B2 (en) 2002-12-21 2003-12-18 Small molecule modulators of hepatocyte growth factor (scatter factor) activity
PCT/US2003/040917 WO2004058721A2 (en) 2002-12-21 2003-12-19 Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity

Publications (3)

Publication Number Publication Date
AU2003301224A1 AU2003301224A1 (en) 2004-07-22
AU2003301224B2 AU2003301224B2 (en) 2011-02-17
AU2003301224C1 true AU2003301224C1 (en) 2011-09-22

Family

ID=32685400

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003301224A Ceased AU2003301224C1 (en) 2002-12-21 2003-12-19 Pyrazole derivatives modulators of Hepatocyte Growth Factor (Scatter Factor) activity

Country Status (10)

Country Link
US (6) US7192976B2 (enExample)
EP (2) EP1572199B1 (enExample)
JP (3) JP5160019B2 (enExample)
CN (1) CN1747730B (enExample)
AU (1) AU2003301224C1 (enExample)
CA (1) CA2511199C (enExample)
DK (2) DK2292227T3 (enExample)
HU (1) HUE030700T2 (enExample)
IL (1) IL169316A (enExample)
WO (1) WO2004058721A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192976B2 (en) 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US20110230407A1 (en) * 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
US7879898B1 (en) 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
EP2313093A4 (en) * 2008-07-10 2012-03-28 Angion Biomedica Corp METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY
WO2010068287A2 (en) * 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2011006072A2 (en) * 2009-07-10 2011-01-13 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
US20120190668A1 (en) * 2009-08-12 2012-07-26 Oehlen Lambertus J W M Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
JP2014509297A (ja) * 2010-10-05 2014-04-17 アンジオン バイオメディカ コーポレイション 肝細胞増殖因子（散乱因子）活性の小分子モジュレーターの使用方法
JP6173298B2 (ja) * 2011-04-02 2017-08-02 ワシントン ステート ユニバーシティ 治療薬としての肝細胞増殖因子模倣体
WO2012151349A1 (en) 2011-05-03 2012-11-08 Liu Shu Q Neuroprotection by hepatic cells and hepatocyte secretory factors
UY34200A (es) * 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
RU2678830C2 (ru) 2013-03-15 2019-02-04 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
KR20150130405A (ko) 2013-03-15 2015-11-23 베르선 코포레이션 트롬빈의 억제제로서의 할로게노피라졸
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
HK1246164A1 (zh) 2015-02-27 2018-09-07 Verseon Corporation 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
KR20220004083A (ko) 2019-04-11 2022-01-11 앤지온 바이오메디카 코포레이션 (e)-3-[2-(2-티에닐)비닐]-1h-피라졸의 고체 형태
WO2021087392A1 (en) * 2019-10-31 2021-05-06 Angion Biomedica Corp. Improving renal function after kidney transplantation
WO2021183774A1 (en) * 2020-03-12 2021-09-16 Angion Biomedica Corp. Treating acute respiratory distress
EP4228626A2 (en) * 2020-10-14 2023-08-23 Angion Biomedica Corp. Preparation of terevalefim and formulations thereof
CA3196582A1 (en) * 2020-11-02 2022-05-05 Leen Kawas Bicyclic compounds and uses thereof for the treatment of diseases
WO2022217070A1 (en) * 2021-04-09 2022-10-13 Angion Biomedica Corp. Hgf/sf mimetic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD138770A1 (de) * 1978-09-20 1979-11-21 Juergen Liebscher Verfahren zur herstellung von 5-styryl-pyrazolen und ihren vinylogen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138770C (enExample) *
JPS48713Y1 (enExample) 1967-12-19 1973-01-09
JPS48713U (enExample) 1971-05-22 1973-01-08
JPH02193994A (ja) 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd ピリダジノン誘導体
FR2669633B1 (fr) * 1990-11-23 1993-01-22 Adir Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5476076A (en) * 1994-12-06 1995-12-19 Zhou; Zhishan Internal combustion piston engine utilizing interference movable fit technology
JPH11288112A (ja) 1998-04-06 1999-10-19 Mitsubishi Paper Mills Ltd 電子写真感光体
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
WO2001034650A1 (en) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
EP1355921A2 (en) 2000-06-29 2003-10-29 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US6589997B2 (en) 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
US6610726B2 (en) 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
WO2004009599A1 (en) 2002-07-19 2004-01-29 Targacept, Inc. Five-membered heteroaromatic olefinic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of ncotinic cholinergic receptors
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD138770A1 (de) * 1978-09-20 1979-11-21 Juergen Liebscher Verfahren zur herstellung von 5-styryl-pyrazolen und ihren vinylogen

Also Published As

Publication number Publication date
EP2292227A3 (en) 2011-05-25
US8580834B2 (en) 2013-11-12
CA2511199A1 (en) 2004-07-15
US20190382348A1 (en) 2019-12-19
DK1572199T3 (da) 2014-02-03
US7250437B2 (en) 2007-07-31
CN1747730A (zh) 2006-03-15
AU2003301224A1 (en) 2004-07-22
HK1085651A1 (en) 2006-09-01
US9663471B2 (en) 2017-05-30
US20040180882A1 (en) 2004-09-16
IL169316A0 (en) 2007-07-04
WO2004058721A2 (en) 2004-07-15
JP2015078246A (ja) 2015-04-23
US20080015243A1 (en) 2008-01-17
CA2511199C (en) 2014-02-11
US7265112B2 (en) 2007-09-04
IL169316A (en) 2013-09-30
JP2006513221A (ja) 2006-04-20
DK2292227T3 (en) 2016-12-19
CN1747730B (zh) 2013-05-29
JP2010265322A (ja) 2010-11-25
US7192976B2 (en) 2007-03-20
US20050113369A1 (en) 2005-05-26
EP1572199B1 (en) 2013-11-20
EP1572199A2 (en) 2005-09-14
US20050192331A1 (en) 2005-09-01
EP2292227B1 (en) 2016-08-24
WO2004058721A3 (en) 2004-10-28
US20140256780A1 (en) 2014-09-11
HUE030700T2 (en) 2017-05-29
JP5160019B2 (ja) 2013-03-13
JP5755417B2 (ja) 2015-07-29
EP2292227A2 (en) 2011-03-09

Similar Documents

Publication Publication Date Title
US9663471B2 (en) Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity
AU2003301224B2 (en) Pyrazole derivatives modulators of Hepatocyte Growth Factor (Scatter Factor) activity
US10899750B2 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
US20110237633A1 (en) Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2006036981A2 (en) Small molecule modulators of cytokine activity
AU2011312333A1 (en) Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
HK1085651B (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 APR 2011.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 APR 2011

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired